Patients in the RINVOQ group also received placebo IV infusions; patients in the abatacept group also received oral placebo. Patients were to continue protocol-specified stable background cDMARDs, NSAIDs, acetaminophen or oral/inhaled glucorticoids. Starting at Week 12, patients who did not have at least a 20% decrease in both TJC and SJC as compared with baseline at two consecutive visits were to have background medications adjusted/added. All patients who completed Week 24 were eligible to remain in an open-label long-term extension for up to 5 years, receiving RINVOQ 15 mg OD.
*Randomisation was stratified according to number of previous bDMARDs and geographic region.
†IV abatacept administered at day 1 and Weeks 2, 4, 8, 12, 16 and 20; 500 mg in patients with a body weight of <60 kg, 750 mg in those with a weight of 60 to 100 kg and 1000 mg in those with a weight of >100kg.